» Articles » PMID: 30534421

Tumor Treating Fields Increases Membrane Permeability in Glioblastoma Cells

Overview
Date 2018 Dec 12
PMID 30534421
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma is the most common yet most lethal of primary brain cancers with a one-year post-diagnosis survival rate of 65% and a five-year survival rate of barely 5%. Recently the U.S. Food and Drug Administration approved a novel fourth approach (in addition to surgery, radiation therapy, and chemotherapy) to treating glioblastoma; namely, tumor treating fields (TTFields). TTFields involves the delivery of alternating electric fields to the tumor but its mechanisms of action are not fully understood. Current theories involve TTFields disrupting mitosis due to interference with proper mitotic spindle assembly. We show that TTFields also alters cellular membrane structure thus rendering it more permeant to chemotherapeutics. Increased membrane permeability through the imposition of TTFields was shown by several approaches. For example, increased permeability was indicated through increased bioluminescence with TTFields exposure or with the increased binding and ingress of membrane-associating reagents such as Dextran-FITC or ethidium D or with the demonstration by scanning electron microscopy of augmented number and sizes of holes on the cellular membrane. Further investigations showed that increases in bioluminescence and membrane hole production with TTFields exposure disappeared by 24 h after cessation of alternating electric fields thus demonstrating that this phenomenom is reversible. Preliminary investigations showed that TTFields did not induce membrane holes in normal human fibroblasts thus suggesting that the phenomenom was specific to cancer cells. With TTFields, we present evidence showing augmented membrane accessibility by compounds such as 5-aminolevulinic acid, a reagent used intraoperatively to delineate tumor from normal tissue in glioblastoma patients. In addition, this mechanism helps to explain previous reports of additive and synergistic effects between TTFields and other chemotherapies. These findings have implications for the design of combination therapies in glioblastoma and other cancers and may significantly alter standard of care strategies for these diseases.

Citing Articles

Immune Cell Interplay in the Fight Against GBM.

Vallieri N, Datsi A Cancers (Basel). 2025; 17(5).

PMID: 40075663 PMC: 11899300. DOI: 10.3390/cancers17050817.


Optimized Methods to Quantify Tumor Treating Fields (TTFields)-Induced Permeabilization of Glioblastoma Cell Membranes.

Martinez-Paniagua M, Khan S, Henning N, Konagalla S, Patel C Methods Protoc. 2025; 8(1).

PMID: 39997634 PMC: 11858626. DOI: 10.3390/mps8010010.


Tumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells.

Amodeo R, Morosi L, Meroni M, Bello E, Timo S, Frapolli R Am J Cancer Res. 2025; 15(1):271-285.

PMID: 39949944 PMC: 11815374. DOI: 10.62347/ODWL5634.


Advancements and challenges in brain cancer therapeutics.

Bai F, Deng Y, Li L, Lv M, Razzokov J, Xu Q Exploration (Beijing). 2024; 4(6):20230177.

PMID: 39713205 PMC: 11655316. DOI: 10.1002/EXP.20230177.


The Synergy of Thermal and Non-Thermal Effects in Hyperthermic Oncology.

Minnaar C, Szigeti G, Szasz A Cancers (Basel). 2024; 16(23).

PMID: 39682096 PMC: 11639953. DOI: 10.3390/cancers16233908.


References
1.
Dive C, Watson J, Workman P . Multiparametric analysis of cell membrane permeability by two colour flow cytometry with complementary fluorescent probes. Cytometry. 1990; 11(2):244-52. DOI: 10.1002/cyto.990110205. View

2.
Kirson E, Schneiderman R, Dbaly V, Tovarys F, Vymazal J, Itzhaki A . Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009; 9:1. PMC: 2647898. DOI: 10.1186/1756-6649-9-1. View

3.
Schneiderman R, Shmueli E, Kirson E, Palti Y . TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. BMC Cancer. 2010; 10:229. PMC: 2893108. DOI: 10.1186/1471-2407-10-229. View

4.
Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts P, Schmelz E . Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer. 2016; 139(12):2850-2858. PMC: 5095795. DOI: 10.1002/ijc.30406. View

5.
Mrugala M, Engelhard H, Tran D, Kew Y, Cavaliere R, Villano J . Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe). Semin Oncol. 2014; 41 Suppl 6:S4-S13. DOI: 10.1053/j.seminoncol.2014.09.010. View